2.2
-0.08 (-3.51%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.03 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.58 | ||
| P/tB | N/A | ||
| EV/EBITDA | 0.12 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -167.91% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | -773.17% | ||
| PM (TTM) | -798.18% | ||
| GM | N/A | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.66 | ||
| Quick Ratio | 3.56 | ||
| Altman-Z | -26.91 |
ChartMill assigns a fundamental rating of 2 / 10 to TTPH.
ChartMill assigns a valuation rating of 3 / 10 to Tetraphase Pharmaceu (TTPH). This can be considered as Overvalued.
Tetraphase Pharmaceu (TTPH) has a profitability rating of 1 / 10.
The financial health rating of Tetraphase Pharmaceu (TTPH) is 2 / 10.
The Earnings per Share (EPS) of Tetraphase Pharmaceu (TTPH) is expected to grow by 82.71% in the next year.